Pharmaceutical company Moderna Inc (NASDAQ: MRNA) announced on Tuesday that it has achieved successful Phase 3 trial results for mRNA-1283, its next-generation COVID-19 vaccine. Compared to its licensed vaccine mRNA-1273.222, mRNA-1283 induces a stronger immune response against SARS-CoV-2, particularly in individuals over 65.
The NextCOVE trial involved over 11,400 participants aged 12 and above across the US, UK and Canada. mRNA-1283 demonstrates a similar safety profile to Moderna's approved COVID-19 vaccines.
mRNA-1283's storage, shelf life, and pre-filled syringe presentation could ease healthcare provider burden and enhance accessibility in various settings. Detailed trial data will be presented at Moderna's Vaccines Day event on 27 March 2024.
Moderna's mRNA platform has revolutionised medicine development, delivering rapid and efficient solutions for infectious diseases, immuno-oncology, rare diseases and autoimmune conditions. The company's mission is to create a healthier future through innovative mRNA medicines.
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034